Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
Rik Johannes Leonardus van der LansJosje Janna OttenGwijde Flavius Jacobus Petrus Maria AdriaensenDinand Rienk HovenLinda Berendina BenoistWytske Johanna FokkensSietze ReitsmaPublished in: Allergy (2023)
This first long-term real-life prospective observational cohort study shows high therapeutic efficacy of dupilumab for severe CRswNP in the first 2 years. Therapeutic efficacy is principally established within 24 weeks and endures while tapering dupilumab conditional to treatment response and CRS control.